Annexon, Inc. (ANNX) , a clinical-stage company, is focused on developing novel therapies to treat patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. The company has channeled its resources to prioritize the development of three candidates in its pipeline, such as ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy (GA) and first-in-kind oral complement small molecule, and ANX1502 for several autoimmune indications. Over the past three m ...